Abstract
In the era of targeted therapy and a multitude of agents to manage anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (aNSCLC), optimal treatment sequencing to achieve the best patient outcomes is yet to be elucidated. Relevant contemporary randomised trials compare single lines of treatment head-to-head but are not designed to investigate this important question.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
